Contrasting ANI Pharmaceuticals (NASDAQ:ANIP) and RenovaCare (OTCMKTS:RCAR)

ANI Pharmaceuticals (NASDAQ:ANIP) and RenovaCare (OTCMKTS:RCAR) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends and earnings.

Earnings and Valuation

This table compares ANI Pharmaceuticals and RenovaCare”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANI Pharmaceuticals	$614.38 million	2.40	-$18.52 million	($1.27)	-53.57
RenovaCare	N/A	N/A	N/A	N/A	N/A

RenovaCare has lower revenue, but higher earnings than ANI Pharmaceuticals.

Institutional & Insider Ownership

76.1% of ANI Pharmaceuticals shares are owned by institutional investors. 11.1% of ANI Pharmaceuticals shares are owned by insiders. Comparatively, 0.9% of RenovaCare shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for ANI Pharmaceuticals and RenovaCare, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANI Pharmaceuticals	0	1	7	1	3.00
RenovaCare	0	0	0	0	0.00

ANI Pharmaceuticals presently has a consensus target price of $78.88, indicating a potential upside of 15.92%. Given ANI Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe ANI Pharmaceuticals is more favorable than RenovaCare.

Profitability

This table compares ANI Pharmaceuticals and RenovaCare’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ANI Pharmaceuticals	-3.12%	21.35%	7.52%
RenovaCare	N/A	N/A	N/A

Summary

ANI Pharmaceuticals beats RenovaCare on 9 of the 10 factors compared between the two stocks.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

About RenovaCare

RenovaCare, Inc., a development-stage biotech and medical device company, focuses on the research, development, and commercialization of autologous cellular therapies for use in medical and aesthetic applications. It is developing CellMist System, a treatment methodology for cell isolation for the regeneration of human skin cells; and SkinGun, a solution sprayer device for delivering the cells to the treatment area. RenovaCare, Inc. has a strategic collaboration StemCell Systems GmbH for isolating and spraying self-donated stem cells to regenerate tissues and organs. The company was formerly known as Janus Resources, Inc. and changed its name RenovaCare, Inc.,to RenovaCare, Inc. in January 2014. RenovaCare, Inc. was incorporated in 1983 and is based in Scottsdale, Arizona.